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Randomized Phase II Study of Two Different Schedules of
Gemcitabine and Oral S-1 in Chemo-naïve Patients with
Advanced Non-small Cell Lung Cancer
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Yoshiko Urata, MD,* Sho Yoshimura, MD,* Yasuhiro Funada, MD,† Akito Hata, MD,*
Masahiko Ando, MD,§ and Shunichi Negoro, MD*
Introduction: This study was conducted to evaluate the efficacy and
safety and to compare dosing schedules of gemcitabine combined
with S-1 in chemo-naïve non-small cell lung cancer patients.
Methods: Patients with chemo-naïve stage IIIB/IV non-small cell
lung cancer were randomized into two treatment arms. Patients were
given oral S-1 (60 mg/m2/d, twice a day) from days 1 to 14 with
gemcitabine (1000 mg/m2/d) on days 1 and 8 (arm A) or on days 8
and 15 (arm B). This cycle was repeated every 21 days.
Results: A total of 80 patients were entered in this trial. The primary
end point of this study was response rate. The response rates of arm
A and arm B were 22.0 and 28.9%, respectively (p  0.606).
Median time to treatment failure in arm A was 3.6 months and 4.8
months in arm B. Median time to progression in arm Awas 4.1 months
and 5.5 months in arm B.Median survival time in armA and arm Bwas
15.5 months and 18.8 months, respectively. The toxicity profile was
relatively mild and did not differ very much between two arms.
Conclusion: The combination of gemcitabine and S-1 was deter-
mined to be feasible and effective for advanced non-small cell lung
cancer. We selected arm B for further studies because of its higher
response rate and survival data.
Key Words: S-1, Gemcitabine, Non-small cell lung cancer
(NSCLC), Phase II study, Dosing schedule.
(J Thorac Oncol. 2010;5: 696–701)
Lung cancer is one of the leading causes of cancer-relatedmortality worldwide. Patients suffering from non-small
cell lung cancer (NSCLC) mainly presented an advanced
stage of the disease at diagnosis.1 Standard chemotherapy for
favorable patients with advanced NSCLC is the platinum-
based doublet regimen.2 Considering the toxicities of cispla-
tin-based chemotherapy and the poor prognosis of advanced
NSCLC, explorations of active and less toxic substitutable
combinations that include new, active compounds with novel
mechanisms of action are urged.
Gemcitabine (GEM), a deoxycytidine analog structur-
ally resembling cytosine arabinoside (Ara-C), has been
shown to have a high antitumor activity and favorable toxic-
ity profile.3 Monotherapy of GEM has demonstrated signifi-
cant improvement of symptoms,4 and the combination of
platinum and GEM has shown the best progression-free
survival outcome of any platinum regimen in advanced
NSCLC in meta-analysis to date.5
S-1 is a novel oral derivative of the 5-fluorouracil
(5-FU) prodrug to which tegafur was combined with two
modulators.6 One of the modulator is gimeracil, which in-
crease concentrations of 5-FU in blood, and the other is
oteracil potassium, which reduce gastrointestinal toxicity. S-1
has shown its antitumor activities with relatively mild adverse
effects in a variety of solid tumors. A phase II study in Japan
showed 22% of response rate (RR) and median survival time
(MST) with 10.2 months for monotherapy.7 Moreover, RR of
47% and MST of 11 months have been reported in a combi-
nation with cisplatin,8 contributing to use in Japan on
NSCLC.
The combination of GEM and 5-FU demonstrates a
marked synergistic cytotoxic effect in a sequence-dependent
manner in the in vitro assay.9 It has also shown a significant
increase in hENT1, a major modulator of cellular uptake of
GEM, and GEM cellular uptake after S-1 or 5-FU treatment
in pancreatic cancer cell lines.10 Significant tumor growth
inhibition has been reported in mice treated with S-1 followed
by GEM compared with both untreated and S-1/GEM-treated
mice in other schedules.10 A phase I/II trial using combina-
tion therapy with S-1/GEM in advanced pancreatic cancer
demonstrated mild toxicity and favorable efficacy at the
recommended dose of S-1 (60 mg/m2 on days 1 to 14) and
GEM (1000 mg/m2 on days 8 and 15).11 The combination
may result in a synergistic effect by sequence-dependent
manner. This synergistic effect, however, has some concerns
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about increased toxicity. This study, therefore, was conducted
to evaluate the efficacy and safety and to compare dosing
schedules of GEM combined with S-1 in chemo-naïve
NSCLC patients.
PATIENTS AND METHODS
Eligibility
Patients were considered eligible if they met the fol-
lowing criteria: histologically or cytologically proven
NSCLC, stage IIIB disease who were not candidates for
thoracic radiation or stage IV disease or postoperative recur-
rence, naïve to chemotherapy, at least one measurable lesion,
age more than 20 years, Eastern Cooperative Oncology
Group performance status (PS) of 0 to 1, life expectancy of
more than or equal to 3 months, ability to take oral medica-
tion, and adequate organ function defined as leukocyte count
more than or equal to 4000/mm3, platelet count more than or
equal to 10,000/mm3, hemoglobin more than or equal to 9.0
g/dl, aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) levels less than twofold the upper limit of
normal, total bilirubin less than 1.5 mg/dl, serum creatinine
less than the upper limit of normal or creatinine clearance
more than or equal to 60 ml/min, and partial pressure of
arterial oxygen more than or equal to 60 torr. Patients were
excluded if they had interstitial pneumonia, history of severe
allergic reactions to drugs, severe infections or other compli-
cations, judged as seriously interfering with this treatment.
Symptomatic brain metastasis or active concurrent malignan-
cies were also excluded. All patients provided written in-
formed consent, and the Institutional Review Board for Hu-
man Experimentation approved the protocol and conducted in
accordance with the Declaration of Helsinki.
Protocol Treatment
Patient were assigned randomly to arm A or B and were
stratified by disease stage (stage IIIB versus IV [including
postoperative recurrence]), PS (0 versus 1), gender (female
versus male), and age (75  versus  75).
Patients received 60 mg/m2 S-1 orally twice daily on
days 1 to 14. S-1 was available as capsules containing 20 or
25 mg of tegafur, so that patients were treated with the
following doses: 60 mg (body surface area [BSA] 1.25m,2
dividing 40 and 20 mg), 80 mg (1.25 BSA 1.50 m2), and
100 mg (BSA 1.50 m2). GEM was administrated at a dose
of 1000 mg/m2 as a 30-minute intravenous infusion on days
1 and 8 (arm A) or on days 8 and 15 (arm B). Treatment was
cycled at 3-week intervals. The scheduled treatment of GEM
was delayed for up to 1 week until recovery if a patient
presented a leukocyte count less than 2000/mm3, platelet
count less than 75,000/mm3, AST/ALT more than or equal to
100 IU/liter, T-bilirubin more than or equal to 1.5 mg/dl,
and/or other non-hematologic toxicities grade more than or
equal to 3. The subsequent cycles were begun if a patient
presented a leukocyte count more than or equal to 3000/mm3,
platelet count more than or equal to 100,000/mm3, AST/ALT
less than 100 IU/liter, T-bilirubin less than 1.5 mg/dl, creat-
inine less than 1.5 mg/dl, and/or other non-hematologic
toxicities grade less than or equal to 2. A 2-week delay in
initiating the subsequent course was allowed. Otherwise, the
patient was withdrawn from the study. Patients were sched-
uled to receive at least three cycles and up to a maximum of
six cycles.
In regard to dose modification of GEM in the subse-
quent cycles in both arms, if, during the previous course, the
patient presented grade 4 leukopenia sustained for more than
or equal to 4 days, febrile neutropenia, thrombocytopenia less
than or equal to 25,000/mm3, non-hematologic toxicities
grade more than or equal to 3, or cancellation of GEM admin-
istration, the dose of GEM was reduced to 800 mg/mm3. Any
patients with non-hematologic toxicities grade more than or
equal to 4 or interstitial pneumonia grade more than or equal
to 2 were withdrawn from the study. If more than three of the
first six patients experienced the following toxicities—grade
4 leukopenia sustained for more than or equal to 4 days,
febrile neutropenia, and delay of starting a subsequent course
by more than 14 days—then patient recruitment for the
treatment group was stopped early.
Response and Toxicity Evaluation
The pretreatment evaluation consisted of complete
medical history and physical examination, complete blood
count, blood chemistry, blood gas analysis, chest x-ray,
electrocardiography, computed tomography (CT) scans of the
chest, magnetic resonance imaging or CT scan of the brain,
CT scans or ultrasound examination of the abdomen, and
bone scintigram. Throughout the treatment period, patients
were monitored weekly through physical examination, in
which toxic effects, complete blood count, and blood chem-
istry were recorded. Studies of drug-related toxicities were
evaluated according to National Cancer Institute Common
Toxicity Criteria (version 3.0) and standard RECIST was
used for response evaluation. We obtained CT scans for the
evaluation of measurable lesion every 1 to 2 cycles. A
confirmatory scan was performed at least 4 weeks after any
assessment showing an initial partial response or complete
response. After the study treatment, all patients were ob-
served with chest x-ray (every 1 month) and CT scans (every
3 months) until disease progression. An extramural review
was conducted to validate staging and responses.
Statistical Methods
This study was designed as a multicenter randomized
phase II trial. The primary end point was objective RR.
According to the criteria of Simon et al.,12 the required
sample size was established as 40 patients per arm to allow
selection of the better treatment with 90% accuracy if abso-
lute RR difference of the better treatment is at least 15% and
expected baseline RR, 30%. Secondary end points were
treatment completion rate, safety, time to progression (TTP),
and overall survival (OS). Randomization was performed
centrally using the minimization method of balancing disease
stage, PS, gender, age, and institution. Fisher’s exact test was
used to compare patient characteristics, RR, treatment com-
pletion rate, and adverse effects. TTP and OS were estimated
using the Kaplan-Meier method and compared between treat-
ment arms using the log-rank test. Two-tailed p values less
than 0.05 were considered statistically significant. Statistical
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analysis was performed using JMP version 7.0.1 (SAS Insti-
tute, Inc., Cary, NC).
RESULTS
Patient Characteristics
Between June 2005 and November 2006, 80 patients
were enrolled (41 in arm A and 39 in arm B). One in 39
patients in arm B showed rash before any study treatment and
withdrawn from this study. This patient was reassigned to the
study after rash was recovered. The patient demographics are
summarized in Table 1. In the study population, randomiza-
tion was well balanced across patient characteristics.
Treatment Delivery
Treatment administration is summarized in Table 2.
The median number of cycles of chemotherapy administrated
was four in both arms. Three or more cycles were delivered
to 70.7 and 71.1% of patients in arm A and B, respectively.
Five of the patients were administered more than 6 courses (7
to 22) until progressive disease on their request (3 in arm A,
2 in arm B). More patients in arm B required a delay in the
initiating of subsequent cycles because of slow recovery of
hematologic toxicities than the patients in arm A. The relative
dose intensity (RDI) delivered on an mg/m2/wk basis of
GEM, and S-1 was significantly greater in arm A than in arm
B (GEM, p  0.0010; S-1, p  0.0105).
Toxicity Results
Hematologic and non-hematologic toxicities are sum-
marized in Table 3. The grade 3 or 4 hematologic toxicities
were neutropenia (56%), febrile neutropenia (6%), thrombo-
cytopenia (11%), and anemia (4%). A higher rate of grade 3
or 4 thrombocytopenia was observed in arm B. Grade 3
pneumonitis was observed in 2 patients in arm A, infection in
4 patients in both arms, and mild rash in 42 patients (53.2%),
with a similar incidence in both arms.
Efficacy Results
Four of the 79 patients did not undergo response assess-
ment because of a decrease in PS (n  2), the use of radiation
therapy (n 1), or complication in the form of severe pneumo-
nia (n  2). Table 4 lists the efficacy data. The RR was 22.0%
(95% confidence interval [CI]  10.6–37.6%) in arm A and
28.9% (95% CI  15.4–45.9%) in arm B (p  0.606).
The OS, TTP, and time to treatment failure (TTF) curve
for the two treatment arms are shown in Figure 1. Median
TTF in arm A was 3.6 months (95% CI  2.8–5.6) and arm
B, 4.8 months (95% CI  3.8–6.3). Median TTP in arm A
was 4.1 months (95% CI  2.8–5.6) and arm B, 5.5 months
(95% CI  3.8–6.3). MST in arm A was 15.5 months (95%
CI  8.0–23.1) and arm B, 18.8 months (95% CI  11.7–
24.5). The 1-year survival rate was 53.8% (95% CI 
38.4–68.9%) in arm A versus 65.8% (95% CI  50.7–
80.9%) in arm B, and 2-year survival rate was 34.2% (95%
CI 19.6–48.7%) in arm A as opposed to 31.6% (95% CI
16.8–46.4%) in arm B.
Additional Treatment Provided Poststudy
After the study treatment, 60 patients (75.9%) received
chemotherapy. Thirty-six patients were put on a platinum
doublet (17 in arm A and 19 in arm B) for 2nd-line chemo-
therapy. Fifteen patients were put on gefitinib (10 in arm A
and 5 in arm B). Four patients were given a 3rd-generation
drug (1 in arm A and 3 in arm B), and three were added to
TABLE 1. Patients Characteristics According to Treatment
Group
Characteristic
Arm A
(n  41)
Arm B
(n  38)
pn % n %
Gender
Male 22 53.7 23 60.5 0.65
Female 19 46.3 15 39.5
Age (yr)
Median 64 65 0.30
75 3 7.3 6 15.8
75 38 92.7 32 84.2
Cell type
Adeno 37 90.2 27 71.1 0.07
SCC 4 9.8 10 26.3
Others 0 0.0 1 2.6
Stage
IIIB 9 22.0 9 23.7 1.00
IV 28 68.3 25 65.8
Postoperative recurrence 4 9.8 4 10.5
ECOG PS
0 13 31.7 8 21.1 0.32
1 28 68.3 30 78.9
Adeno, adenocarcinoma; SCC, squamous cell carcinoma; ECOG PS, Eastern
Cooperative Oncology Group performance status.
TABLE 2. Treatment Delivery and Dose Intensity
Measure
Arm A Arm B
pn % n %
No. receiving
treatment
41 38 —
No. of cycles
(median)
4.0 4.0 —
No. of cycles
(range)
1–22 1–15
No. completing
3 cycles
29 70.7 26 68.4 —
Dose reductions
(GEM)
2 4.9 2 5.3 1.00
Cycle delayed 25 61.0 29 78.9 0.16
Length of cycles
(median, days)
22.3 26.4 0.0001
Length of cycles
(range, days)
21–29 20–35
Median relative
dose intensity
GEM 0.93 0.80 0.0010
S-1 0.91 0.83 0.0105
GEM, Gemcitabine.
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S-1/GEM rechallenge regimen (1 in arm A and 2 in arm B).
Most patients (41; 51.9%) ultimately received a platinum
doublet in their subsequent poststudy treatment regimens.
DISCUSSION
This study is the first evaluation of the safety and
efficacy of combination with a new agent, S-1, with GEM in
the population of NSCLC patients. The key goal of this study
was to conduct a comparative examination as to which
combination schedule could be used in further studies.
Although the RR in both arms were lower than the
expected value, given that single agent S-1 produced 22% RR in
the previous phase II study,7 it is still possible that the combi-
nation regimen has a synergistic effect. The disease control rate
(complete response  partial response  stable disease) of our
study ranging between 75 and 79% was favorable and higher by
15 to 20% than that of S-1 monotherapy. The RR in arm B was
similar to the RR in platinum doublet arms of two recent
Japanese phase III studies (Four-Arm Cooperative Study
[FACS]13 and West Japan Thoracic Oncology Group Trial
020314) and an S-1 non-platinum doublet.15
Majority of the patients showed rash, which was an
adverse effect particularly observed in combination therapy
used in this study. It was, however, mild and did not increase
its severity with the repeated administrations. We expected
the advantage of this non-platinum regimen, S-1 plus GEM,
to be the facilitation of favorable maintenance of quality of
living because of the low incidence of toxicity in terms of
gastrointestinal, renal, and hematological toxicities. Although
the S-1 plus GEM combination showed higher rates of
TABLE 3. Adverse Events According to Treatment Group
Toxicity
Arm A (n  41) Arm B (n  38)
p
(Grade 3/4)All, n (%)
Grade, 3⁄4
n (%) All, n (%)
Grade, 3⁄4
n (%)
Hematologic
Leukocytes 36 (87.8) 11 (26.8) 33 (86.8) 11 (28.9) 1.00
Neutrophils 40 (97.6) 25 (61.0) 36 (94.7) 19 (50.0) 0.37
Platelets 33 (80.5) 2 (4.9) 33 (86.8) 7 (18.4) 0.08
Hemoglobin 33 (80.5) 1 (2.4) 33 (86.8) 2 (5.3) 0.61
Febrile neutropenia 3 (7.3) 3 (7.3) 2 (5.3) 2 (5.3) 0.61
Non-hematologic
GOT 14 (34.1) 13 (34.2) —
GPT 17 (41.5) 20 (52.6) 1 (2.6) 0.48
Bilirubin 9 (22.0) 16 (42.1) —
Creatinine 2 (4.9) 1 (2.6) —
Nausea 22 (53.7) 1 (2.4) 19 (50.0) 2 (5.3) 0.61
Anorexia 25 (61.0) 2 (4.9) 24 (63.2) 2 (5.3) 1.00
Diarrhea 9 (22.0) 6 (15.8) —
Constipation 27 (63.4) 1 (2.4) 23 (60.5) 1 (2.6) 1.00
Fatigue 33 (80.5) 2 (4.9) 32 (84.2) 3 (7.9) 0.67
Infection 7 (17.1) 4 (9.7) 11 (28.9) 4 (10.5) 1.00
Rash 20 (48.8) 22 (57.9) —
Pneumonitis 3 (7.3) 2 (4.9) 0.49
Stomatitis 3 (7.3) 6 (15.8) —
Adverse events were graded by National Cancer Institute Toxicity Criteria version 3.0.
GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase.
TABLE 4. Response and Survival According to Treatment Group
Measure
Arm A
(n  41)
Arm B
(n  38)
No. receiving treatment 41 38
No. not assessable 2 2
No. assessable 39 36
Response
Response rate (%) 22.0 28.9
95% CI (%) 10.6–37.6 15.4–45.9
Complete response (n) 0 1
Partial response (n) 9 10
Stable disease (n) 22 19
Disease control rate (%) 75.6 78.9
Progressive disease (n) 8 6
Time to progression
Median (mo) 4.1 5.5
95% CI 2.8–5.6 3.8–6.3
Time to treatment failure
Median (mo) 3.6 4.8
95% CI 2.8–5.6 3.6–6.3
Overall survival
Median (mo) 15.5 18.8
95% CI 8.0–23.6 11.7–23.9
1-yr survival rate (%)
Rate 53.7 65.8
95% CI 38.4–68.9 50.7–80.9
2-yr survival rate (%)
Rate 34.2 31.6
95% CI 19.6–48.7 16.8–46.4
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leukopenia and neutropenia than S-1 plus cisplatin8 or S-1
plus irinotecan,15 the incidence of febrile neutropenia was
similar to that of S-1 plus irinotecan15 and grade 3 or 4
neutropenia, lower than the platinum doublet arms in the
FACS13 and West Japan Thoracic Oncology Group Trial
020314 studies. And, incidence of grade 3 or 4 non-hemato-
logic toxicity in terms of diarrhea, anorexia, and fatigue was
lower than that reported in the abovementioned studies.
Although the incidence of hematologic toxicity appears rel-
atively higher, the toxicity profile indicates that it is a regi-
men that is easy to continue without adversely affecting the
patient’s condition. Grade-3 pneumonitis was observed in 2
patients; however, no other severe non-hematologic toxicities
were confirmed. There were many cases of delay to initiate
the subsequent treatment courses because of prolonged he-
matologic toxicity in arm B, resulting in a significant de-
crease in RDI. Regardless of the lower RDI, favorable trends
were observed in the arm B efficacy-related end points. Both
the depressed RDI and better efficacy in arm B suggest that
the preclinical sequence-dependent synergistic effect reported
by Nakahira et al.10 may also be present in the actual clinical
setting and may substantiate the relatively favorable efficacy
observed with the combination therapy used in our study.
Our study demonstrated relatively favorable TTP and
TTF, and very favorable OS. The OS of both arms of this
study were superior to the OS observed in each arm in the
FACS study. Most patients were followed up with plati-
num-based doublets 2nd line. This may have led to the
favorable OS. The combination therapy used in the study
seems to be not very toxic and does not worsen activities
of daily living. Thus, this suggests that a major advantage
of the therapy is that it allows them to maintain a favorable
systemic condition conducive to subsequent therapy in
which platinum is combined. Use of less toxic regimens
from 1st-line that allow for the continuation of a main-
tained PS level and effective subsequent treatments may be
a treatment option in the future.
Our study showed the S-1/GEM combination therapy
not only to be relatively non-toxic but also have a favorable
MST of 18.8 months, particularly in arm B. These findings
suggest that this combination therapy may be a promising
substitute for platinum-based doublet in 1st-line treatment in
NSCLC.
In conclusion, the combination of GEM and S-1 was
determined to be feasible and effective for advanced NSCLC.
We determined the arm B dosing schedule to be a reasonable
treatment regimen for future studies because of the better RR,
median TTF, and MST.
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